PPD®

Central Committee on research Involving Human Subjects (CCMO)
Attn. Competent Authority
Parnassusplein 5
2511 VX Den Haag

Bennekom, 21 March 2022

Re:	Submission of Clinical Study Report Synopsis
Protocol number:	GLPG1690-CL-304
EudraCT number:	2018-001406-29
NL number:	NL67478.078.18

Dear members of the Central Committee on Research Involving Human Subjects,

On behalf of our client, Galapagos NV (GLPG), please find enclosed the clinical study report synopsis for the study dd 18-Oct-2021: for the study entitled "A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis', registered under NL67478.078.1823.

Please find the list of enclosed documents supporting this application in the Table of Contents below.

I would like to inform you that the clinical trial results have been posted in EudraCT according to Directive 2001/20/EC. A publication or summary of the results will be uploaded to ToetsingOnline once available.

With this submission we declare that all relevant documents from the above-mentioned research dossier are signed by the authorised people. The signed documents are/will be submitted for review to the responsible review committee specified in question I1 of the general assessment and registration form (ABR form).

PPD (Netherlands) BV Bornweg 12c – 6721 AH BENNEKOM The Netherlands
Tel +31 318 65 5.1.2.e fax +31 318 65 5.1.2.e www.ppdi.com
Bank: 5.1.2.e VAT: NL8117.97.077.B01 RCB: 24346310
IBAN: 5.1.2.e BIC: 5.1.2.e

We would appreciate a confirmation of receipt and hope to have informed you sufficiently this way. Should you have any questions regarding this submission, please do not hesitate to contact us.

Yours sincerely,

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

5.1.2.e

PPD Netherlands BV
Bornweg 12c
6721 AH Bennekom
The Netherlands
Phone: +31 (0) 318 65 5.1.2.e
Fax: +31 (0) 318 65 5.1.2.e
Email: 5.1.2.e @ppdi.com

Table of contents